Pegem Journal of Education and Instruction, Vol. 14, No. 3 , 2024 (pp. 1144-1160)

RESEARCH ARTICLE WWW.PEGEGOG.NET

Distinctive Features of ST-Segment Elevation Myocardial Infarction: Epidemiology, Risk Profiles, Management, and Outcomes

Moataz A. Elkot [1], Muhammad Wafaie Aboleineen [1], Ahmed Shawky Shereef [1], Basel Hatem Saadel Din Muhammad [2]

1 Department of Cardiology, Faculty of Medicine, Zagazig University
2 Department of Cardiology, National Heart Institute

Corresponding author: Basel Hatem Saadel Din Muhammad

ABSTRACT

***Background*:** ST-segment elevation myocardial infarction (STEMI) remains one of the leading causes of cardiovascular mortality worldwide. Although significant advances in prevention, diagnosis, and reperfusion therapies have improved outcomes in many developed countries, substantial geographic and ethnic variations persist in the epidemiology, risk factor distribution, management strategies, and clinical outcomes of STEMI. Middle Eastern populations, particularly Egyptian patients, exhibit unique demographic and cardiovascular characteristics compared with Western populations, including younger age at presentation, higher prevalence of diabetes mellitus and smoking, delayed healthcare seeking behavior, and differences in reperfusion practices. Understanding these distinctive features is essential for developing region-specific prevention and management strategies.

Aim: This review aims to evaluate the unique epidemiological characteristics, cardiovascular risk profiles, management patterns, and clinical outcomes of STEMI in Egypt and Middle Eastern populations while comparing these findings with contemporary data from Western and other international populations.

Available evidence demonstrates that STEMI patients in Egypt and the Middle East commonly present at a younger age and carry a disproportionately high burden of modifiable cardiovascular risk factors, particularly diabetes mellitus, tobacco use, obesity, metabolic syndrome, and dyslipidemia. Delays in symptom recognition, underutilization of emergency medical services, and variability in access to primary percutaneous coronary intervention contribute significantly to treatment disparities and adverse outcomes. Compared with Western populations, Middle Eastern patients frequently exhibit premature atherosclerotic disease, more extensive metabolic abnormalities, and distinct sociocultural determinants influencing healthcare utilization. Recent regional registries have revealed important improvements in reperfusion strategies; however, significant gaps remain in STEMI systems of care, preventive cardiology, and secondary prevention implementation.

Conclusion: STEMI in Egypt and Middle Eastern populations possesses unique epidemiological and clinical characteristics that distinguish it from patterns observed in Western countries. Targeted public health interventions, optimization of STEMI networks, expansion of primary PCI availability, and aggressive control of modifiable cardiovascular risk factors are essential for improving outcomes. Future research should focus on regional registries, precision cardiovascular medicine, and healthcare system innovations tailored to the specific needs of Middle Eastern populations.

Keywords: Distinctive Features, ST-Segment Elevation Myocardial Infarction, Management, and Outcomes

INTRODUCTION

Cardiovascular disease remains the leading cause of mortality worldwide, accounting for approximately one-third of all global deaths. Among cardiovascular disorders, ischemic heart disease represents the most common cause of morbidity and mortality, with ST-segment elevation myocardial infarction (STEMI) constituting one of its most severe acute manifestations. STEMI results from abrupt coronary artery occlusion leading to prolonged myocardial ischemia and necrosis, requiring rapid diagnosis and timely reperfusion to preserve myocardial viability and improve survival. Despite major therapeutic advances over recent decades, STEMI continues to impose a substantial burden on healthcare systems, particularly in low- and middle-income countries undergoing rapid epidemiological transition.[1-4]

The global epidemiology of STEMI demonstrates considerable heterogeneity across regions. Differences in socioeconomic development, healthcare infrastructure, lifestyle behaviors, genetic predisposition, environmental exposures, and cardiovascular risk factor prevalence contribute to substantial variation in disease burden and clinical outcomes. While many Western countries have experienced declining rates of STEMI due to successful preventive strategies and improved cardiovascular care, several developing regions continue to face increasing burdens of coronary artery disease and acute myocardial infarction.[5,6]

The Middle East and North Africa (MENA) region has undergone profound demographic, nutritional, and socioeconomic changes during recent decades. Rapid urbanization, reduced physical activity, dietary westernization, increasing obesity rates, and a growing prevalence of diabetes mellitus have accelerated the burden of atherosclerotic cardiovascular disease. Consequently, STEMI has emerged as a major public health challenge throughout the region. Notably, several studies have demonstrated that patients from Middle Eastern countries frequently develop myocardial infarction at younger ages than Western populations and exhibit distinctive cardiovascular risk profiles characterized by high rates of smoking, diabetes mellitus, obesity, and metabolic syndrome.[7,8]

Egypt represents a particularly important model within the region because of its large population and substantial cardiovascular disease burden. National registry data have demonstrated that Egyptian STEMI patients are younger than their European counterparts and exhibit higher frequencies of diabetes mellitus and tobacco use. Furthermore, delays in hospital presentation, underutilization of emergency medical services, and disparities in access to reperfusion therapies continue to influence clinical outcomes. These observations suggest that STEMI in Egypt reflects not only biological differences in cardiovascular risk but also important healthcare system and socioeconomic determinants.[9]

Although numerous studies have evaluated STEMI epidemiology and management within individual countries, there remains a relative lack of comprehensive reviews specifically examining the distinctive features of STEMI in Egypt and Middle Eastern populations compared with Western and other international cohorts. Understanding these regional differences is essential for tailoring prevention programs, optimizing healthcare delivery systems, and improving patient outcomes.

Research Gap

Current literature lacks an integrated review synthesizing epidemiological patterns, cardiovascular risk profiles, treatment practices, and outcomes of STEMI across Egypt and the Middle East in comparison with other global populations. Existing publications are frequently limited to individual national registries or single-country analyses and do not comprehensively address the underlying factors responsible for observed regional variations.

Aim of the Review

This review aims to examine the distinctive epidemiological characteristics, cardiovascular risk factors, management strategies, and clinical outcomes of STEMI in Egypt and Middle Eastern populations and to compare these findings with contemporary evidence from Europe, North America, and other international regions.

STEMI Epidemiology Across Egypt, the Middle East, and Western Populations

The epidemiology of ST-segment elevation myocardial infarction (STEMI) varies substantially across geographic regions due to differences in demographic characteristics, socioeconomic conditions, healthcare infrastructure, cardiovascular risk factor

prevalence, genetic susceptibility, and preventive healthcare policies. Understanding these regional variations is important because they directly influence disease burden, clinical presentation, treatment strategies, and outcomes. Egypt and Middle Eastern countries exhibit several distinctive epidemiological features that differentiate them from Western populations and contribute to unique challenges in STEMI prevention and management.[10,11]

Globally, cardiovascular disease remains the leading cause of death, accounting for approximately 18 million deaths annually. Although many developed countries have experienced a decline in STEMI incidence over recent decades due to improved risk factor control, smoking reduction, widespread statin use, and effective primary prevention programs, this trend has not been uniformly observed across developing regions. Many countries in the Middle East continue to experience a growing burden of ischemic heart disease driven by increasing rates of diabetes mellitus, obesity, metabolic syndrome, and urbanization-associated lifestyle changes.[1,2,10]

STEMI in Egypt

Egypt represents one of the largest populations in the Middle East and North Africa region and consequently contributes substantially to the regional cardiovascular disease burden. Available evidence indicates that Egyptian STEMI patients frequently present at a younger age than patients in Europe and North America. National registry data have demonstrated that smoking and diabetes mellitus are particularly prevalent among Egyptian STEMI patients, suggesting an accelerated cardiovascular risk profile that promotes premature atherosclerosis and earlier coronary events.[9]

The Egyptian Society of Cardiology STEMI registry remains one of the most important contemporary sources of epidemiological data. This registry demonstrated that Egyptian STEMI patients not only presented at younger ages but also experienced longer delays between symptom onset and hospital presentation. Furthermore, utilization of emergency medical services was significantly lower than that observed in European populations, with many patients arriving through self-transport rather than ambulance activation. These factors contribute to prolonged total ischemic time and adversely affect clinical outcomes.[9]

Another notable observation is the continued use of thrombolytic therapy in several Egyptian centers despite increasing expansion of primary percutaneous coronary intervention (PCI) services. While primary PCI has become the preferred reperfusion strategy globally, access remains heterogeneous across different regions of Egypt, reflecting disparities in healthcare infrastructure and resource availability.[4,9]

STEMI in Gulf Countries

Countries of the Arabian Gulf, including Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Bahrain, and Oman, have experienced rapid economic growth and urbanization during recent decades. These socioeconomic transformations have been accompanied by profound lifestyle changes characterized by reduced physical activity, increased caloric intake, obesity, and diabetes mellitus.[12]

Large regional registries such as the Gulf Registry of Acute Coronary Events (Gulf RACE) have provided valuable insights into STEMI epidemiology in Gulf countries. Similar to Egypt, patients in Gulf states often experience myocardial infarction at younger ages than Western populations. Diabetes mellitus prevalence among STEMI patients is particularly high, frequently exceeding rates reported in Europe and North America.[13]

The Gulf RACE registry demonstrated that approximately one-third to one-half of acute coronary syndrome patients had diabetes mellitus, substantially exceeding prevalence rates reported in many Western registries. Obesity and metabolic syndrome are also highly prevalent and contribute significantly to cardiovascular risk. Despite improvements in healthcare infrastructure and increasing availability of primary PCI, delays in presentation and underutilization of ambulance services remain challenges throughout parts of the region.[13,14]

STEMI in Levant and Other Middle Eastern Countries

Levant countries, including Jordan, Lebanon, Syria, Iraq, and Palestine, exhibit epidemiological patterns broadly similar to those observed in Egypt and Gulf countries, although substantial variability exists because of differences in healthcare systems, economic conditions, and political stability.[15]

Studies from Jordan and Lebanon have demonstrated high rates of smoking among STEMI patients, particularly among younger men. Tobacco consumption remains one of the most important modifiable cardiovascular risk factors in these populations.

Waterpipe smoking is especially prevalent and has emerged as a significant contributor to cardiovascular disease burden throughout the region.[16]

In several Middle Eastern countries, acute coronary syndrome patients present approximately 5–10 years earlier than patients in Europe. This pattern of premature coronary artery disease has been attributed to the combined effects of smoking, diabetes mellitus, obesity, dyslipidemia, and genetic predisposition. These observations suggest that cardiovascular prevention strategies must begin earlier in life than traditionally recommended in many Western populations.[15,16]

STEMI in Europe

Europe has experienced significant declines in STEMI incidence and mortality over recent decades. Improvements in smoking cessation, hypertension control, lipid management, and primary prevention have contributed substantially to these favorable trends. Additionally, widespread implementation of STEMI networks, emergency medical services, and rapid access to primary PCI has transformed acute myocardial infarction care across many European countries.[11,17]

European STEMI patients generally present at older ages than Middle Eastern patients. Although traditional cardiovascular risk factors remain common, diabetes mellitus prevalence tends to be lower than that reported in many Middle Eastern populations. Furthermore, ambulance utilization is significantly higher, leading to shorter symptom-to-balloon times and more efficient reperfusion pathways.[17]

The European Society of Cardiology has established comprehensive systems of care emphasizing rapid diagnosis, prehospital ECG transmission, direct catheterization laboratory activation, and timely primary PCI. These coordinated systems have contributed to substantial reductions in mortality and complications following STEMI.[4,17]

STEMI in North America

North America has also witnessed a decline in STEMI incidence during the past two decades. In the United States and Canada, improvements in preventive cardiology and widespread adoption of evidence-based therapies have reduced both STEMI occurrence and mortality.[18]

Compared with Middle Eastern populations, North American STEMI patients generally present at older ages and demonstrate lower rates of diabetes mellitus. However, obesity remains a major challenge and continues to contribute significantly to cardiovascular disease burden. Healthcare systems in North America emphasize rapid emergency response, advanced STEMI networks, and near-universal availability of primary PCI in urban settings.[18,19]

Although racial and ethnic disparities persist within North America, overall outcomes have improved substantially because of advances in pharmacological therapy, reperfusion strategies, and secondary prevention programs.[19]

STEMI in South Asian Populations

South Asian populations represent an important comparator because they share several epidemiological features with Middle Eastern countries. Numerous studies have demonstrated that South Asians experience myocardial infarction at younger ages and possess a higher lifetime risk of coronary artery disease than many Western populations.[20]

The increased cardiovascular risk observed among South Asians has been attributed to a combination of genetic susceptibility, insulin resistance, diabetes mellitus, abdominal obesity, elevated triglycerides, low HDL cholesterol levels, and chronic inflammatory activation. Similar patterns have been reported among Egyptian and Middle Eastern populations, suggesting potential shared mechanisms underlying premature atherosclerosis.[20,21]

Importantly, cardiovascular mortality among South Asians remains disproportionately high despite improvements in healthcare access and treatment. These observations highlight the importance of early risk factor identification and aggressive preventive interventions in high-risk ethnic populations.[21]

Comparative Epidemiological Perspective

When comparing Egypt and Middle Eastern populations with Europe and North America, several consistent themes emerge. First, STEMI occurs at younger ages in Middle Eastern populations. Second, diabetes mellitus, smoking, obesity, and metabolic syndrome are more prevalent. Third, delays in healthcare seeking behavior and lower emergency medical service utilization remain significant challenges. Finally, although access to primary PCI has improved substantially, variations in healthcare

infrastructure continue to influence treatment delivery and outcomes.[9,13,17]

These epidemiological differences have important clinical implications. Earlier disease onset results in greater socioeconomic impact because affected individuals frequently belong to economically productive age groups. Moreover, the coexistence of multiple cardiometabolic risk factors contributes to more complex coronary artery disease and increases the likelihood of recurrent cardiovascular events. Consequently, prevention strategies in Egypt and the Middle East must focus not only on acute STEMI management but also on aggressive control of modifiable cardiovascular risk factors beginning early in adulthood.[10,21]

Overall, STEMI epidemiology in Egypt and Middle Eastern populations is characterized by younger age at presentation, high prevalence of cardiometabolic risk factors, and healthcare system challenges that distinguish these populations from their Western counterparts. Recognition of these unique features is essential for designing region-specific public health initiatives and optimizing cardiovascular outcomes.

Distinctive Cardiovascular Risk Profiles in Egypt and Middle Eastern Populations

Cardiovascular risk factors constitute the foundation upon which atherosclerotic cardiovascular disease develops and ultimately culminates in acute coronary events such as ST-segment elevation myocardial infarction (STEMI). While traditional risk factors are recognized globally, their prevalence, distribution, and clinical impact vary substantially across populations. One of the most distinctive features of STEMI in Egypt and Middle Eastern countries is the exceptionally high burden of modifiable cardiometabolic risk factors occurring at relatively young ages. These characteristics contribute significantly to premature coronary artery disease, earlier STEMI presentation, and increased long-term cardiovascular morbidity.[15,21]

The INTERHEART study demonstrated that more than 90% of myocardial infarction risk worldwide can be attributed to a limited number of modifiable risk factors including smoking, diabetes mellitus, hypertension, dyslipidemia, abdominal obesity, psychosocial stress, dietary factors, and physical inactivity. However, the relative contribution of these risk factors differs among regions, highlighting the importance of population-specific prevention strategies.[15]

Smoking: A Dominant Driver of Premature STEMI

Smoking remains one of the most important cardiovascular risk factors throughout Egypt and the Middle East. Numerous regional registries have consistently demonstrated smoking prevalence rates among STEMI patients that exceed those reported in many Western populations. This observation is particularly evident among younger male patients, among whom tobacco exposure frequently represents the predominant modifiable risk factor.[22]

The adverse cardiovascular effects of smoking are mediated through multiple mechanisms including endothelial dysfunction, oxidative stress, platelet activation, inflammation, increased sympathetic activity, and promotion of thrombosis. Smoking accelerates atherosclerotic plaque formation while simultaneously increasing plaque vulnerability and the likelihood of acute thrombotic occlusion.[23]

A unique feature of the Middle East is the widespread use of waterpipe tobacco (shisha). Although often perceived as less harmful than cigarettes, waterpipe smoking exposes users to substantial quantities of nicotine, carbon monoxide, particulate matter, and toxic chemicals. Emerging evidence indicates that waterpipe smoking is associated with endothelial dysfunction, arterial stiffness, and increased cardiovascular risk comparable to traditional cigarette smoking.[16,24]

The high prevalence of tobacco use contributes substantially to the younger age at STEMI presentation observed throughout Egypt and neighboring countries. Consequently, comprehensive tobacco-control policies remain among the most effective strategies for reducing future cardiovascular disease burden in the region.[22,24]

Diabetes Mellitus: The Defining Cardiometabolic Challenge

Perhaps the most distinctive cardiovascular risk factor in Middle Eastern STEMI populations is diabetes mellitus. Several countries in the region rank among those with the highest diabetes prevalence worldwide. Egypt, Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates have all reported rapidly increasing rates of type 2 diabetes driven by obesity, sedentary lifestyle, dietary transitions, and population aging.[25]

Diabetes exerts profound effects on the cardiovascular system through endothelial dysfunction, oxidative stress, chronic inflammation, platelet hyperreactivity, impaired fibrinolysis, and accelerated atherosclerosis. As a result, diabetic patients often develop more diffuse coronary artery disease, multivessel involvement, and worse outcomes following myocardial

infarction.[26]

Registry data from Egypt and Gulf countries consistently demonstrate markedly higher diabetes prevalence among STEMI patients compared with many European cohorts. This elevated burden contributes significantly to premature coronary artery disease and partially explains why myocardial infarction frequently occurs 5–10 years earlier in Middle Eastern populations than in Western populations.[9,13]

Importantly, diabetes not only increases the likelihood of STEMI occurrence but also worsens prognosis after infarction. Diabetic patients exhibit higher rates of heart failure, recurrent myocardial infarction, cardiogenic shock, and mortality. Therefore, aggressive diabetes prevention and control represent essential components of cardiovascular risk reduction throughout the region.[25,26]

Obesity and Central Adiposity

The Middle East has experienced a dramatic rise in obesity prevalence during recent decades. Rapid urbanization, reduced occupational physical activity, increased dependence on motorized transportation, and adoption of calorie-dense dietary patterns have contributed to an obesity epidemic affecting both adults and children.[12]

Unlike simple body mass index measurements, central obesity appears particularly important in cardiovascular risk assessment. Visceral adipose tissue functions as an active endocrine organ producing inflammatory cytokines, adipokines, and mediators that promote insulin resistance, endothelial dysfunction, hypertension, and dyslipidemia. Consequently, abdominal obesity is strongly associated with coronary artery disease and acute myocardial infarction.[15]

Many Middle Eastern countries report obesity rates among the highest globally. The coexistence of obesity with diabetes and hypertension creates a synergistic cardiometabolic risk profile that substantially accelerates atherosclerotic disease progression. These observations suggest that effective weight management strategies may have profound effects on future cardiovascular outcomes.[12,25]

Metabolic Syndrome

Metabolic syndrome represents the clustering of abdominal obesity, impaired glucose metabolism, hypertension, and dyslipidemia. The syndrome is particularly prevalent in Middle Eastern populations and serves as a powerful predictor of future cardiovascular events.[27]

The high prevalence of metabolic syndrome reflects the combined effects of sedentary lifestyle, unhealthy dietary patterns, obesity, and genetic susceptibility. Individuals with metabolic syndrome demonstrate heightened inflammatory activation, endothelial dysfunction, insulin resistance, and prothrombotic tendencies, all of which contribute to accelerated atherosclerosis.[27,28]

Among Egyptian STEMI patients, metabolic syndrome is commonly observed and frequently coexists with diabetes mellitus. This clustering of risk factors amplifies cardiovascular risk beyond the effects of individual components alone and contributes to the development of premature coronary artery disease.[9]

Hypertension

Hypertension remains one of the most prevalent cardiovascular risk factors globally and is highly prevalent throughout Egypt and the Middle East. Chronic elevation of blood pressure promotes endothelial injury, vascular remodeling, arterial stiffness, left ventricular hypertrophy, and progression of atherosclerotic disease.[29]

Although hypertension prevalence in Middle Eastern STEMI populations is generally comparable to that reported in Western countries, its impact may be amplified by coexistence with diabetes mellitus, obesity, and metabolic syndrome. In many patients, hypertension remains underdiagnosed or inadequately controlled, contributing to residual cardiovascular risk despite availability of effective pharmacological therapies.[30]

Population aging and increasing obesity prevalence suggest that hypertension will continue to play an important role in future cardiovascular disease burden across the region.[29]

Dyslipidemia and Atherogenic Lipid Profiles

Dyslipidemia is a central determinant of atherosclerotic cardiovascular disease and remains highly prevalent in Middle Eastern

populations. Although elevated low-density lipoprotein cholesterol (LDL-C) remains the principal therapeutic target, regional studies have identified a particularly common pattern characterized by elevated triglycerides, reduced high-density lipoprotein cholesterol (HDL-C), and insulin resistance-related lipid abnormalities.[31]

This lipid profile is strongly associated with obesity, diabetes mellitus, and metabolic syndrome. The resulting atherogenic environment promotes plaque formation, progression, and instability, thereby increasing STEMI risk. Contemporary evidence supports aggressive lipid lowering with high-intensity statin therapy and additional lipid-modifying agents in high-risk populations.[32]

Despite increased awareness of dyslipidemia, achievement of guideline-recommended LDL-C targets remains suboptimal in many Middle Eastern countries. Improved implementation of preventive cardiology strategies is therefore necessary to reduce residual cardiovascular risk.[32]

Genetic and Ethnic Influences

While environmental and lifestyle factors account for much of the observed cardiovascular risk, genetic susceptibility also appears to contribute to regional differences in STEMI epidemiology. Several studies suggest that Middle Eastern populations may possess inherited predispositions influencing lipid metabolism, insulin resistance, inflammatory responses, and thrombosis.[33]

Genetic variations affecting lipoprotein metabolism, including polymorphisms involving apolipoproteins, cholesterol transport pathways, and lipoprotein(a), have been associated with increased coronary artery disease risk. Similarly, genetic determinants of diabetes susceptibility may partially explain the exceptionally high prevalence of diabetes observed throughout the region.[33,34]

Although current clinical practice remains focused primarily on traditional risk factor modification, future advances in precision cardiovascular medicine may enable more individualized prevention strategies based on genetic risk assessment.[34]

Emerging Cardiovascular Risk Factors

Beyond traditional risk factors, increasing attention has focused on emerging biomarkers and novel determinants of cardiovascular disease. Elevated lipoprotein(a), chronic low-grade inflammation, high-sensitivity C-reactive protein (hs-CRP), and inflammatory cytokines such as interleukin-6 have all been associated with increased risk of myocardial infarction.[35]

Psychosocial stress, depression, sleep disturbances, and socioeconomic factors may also contribute significantly to cardiovascular risk in Middle Eastern populations. Rapid societal transformation, urbanization, and changing lifestyle patterns may further influence these non-traditional determinants of cardiovascular disease.[36]

Additionally, chronic kidney disease, environmental pollution, and dietary factors have emerged as important contributors to cardiovascular risk and warrant further investigation within regional populations.[36]

Why Is STEMI Occurring Earlier in the Middle East?

The younger age at STEMI presentation observed across Egypt and much of the Middle East is likely multifactorial. High smoking prevalence among young adults, early development of obesity and diabetes mellitus, widespread metabolic syndrome, insufficient physical activity, and genetic predisposition collectively contribute to accelerated atherosclerosis. Unlike many Western populations where coronary artery disease predominantly affects older individuals, these risk factors often become established during early adulthood in Middle Eastern populations, resulting in earlier manifestation of clinical disease.[9,15,21]

This phenomenon has major public health implications because premature STEMI affects economically productive age groups and generates substantial long-term healthcare and socioeconomic burdens. Consequently, prevention strategies must prioritize early identification and aggressive modification of cardiovascular risk factors before irreversible vascular damage occurs.[12,25]

In summary, the cardiovascular risk profile of STEMI patients in Egypt and the Middle East is characterized by exceptionally high prevalence of smoking, diabetes mellitus, obesity, metabolic syndrome, and dyslipidemia. These factors interact synergistically to promote premature atherosclerosis and earlier onset of myocardial infarction compared with Western populations. Recognition of these distinctive risk profiles is essential for designing effective preventive strategies and improving cardiovascular outcomes throughout the region.

Distinctive Clinical Presentation and Diagnostic Characteristics of STEMI in Egypt and Middle Eastern Populations

Although the fundamental pathophysiological mechanisms of ST-segment elevation myocardial infarction (STEMI) are similar worldwide, substantial regional differences exist in clinical presentation, healthcare-seeking behavior, diagnostic pathways, and early management. These differences significantly influence treatment delays, reperfusion success, and clinical outcomes. Patients from Egypt and other Middle Eastern countries exhibit several distinctive clinical characteristics that differentiate them from Western populations and have important implications for cardiovascular care delivery.[37,38]

Younger Age at Presentation

One of the most consistent findings across Middle Eastern STEMI registries is the younger age at presentation compared with patients in Europe and North America. Multiple studies have demonstrated that acute myocardial infarction frequently occurs approximately 5–10 years earlier in Middle Eastern populations. This observation has been documented in Egyptian registries, Gulf RACE studies, and several national cardiovascular databases throughout the region.[9,13]

The earlier occurrence of STEMI is largely attributed to the high prevalence of smoking, diabetes mellitus, obesity, metabolic syndrome, and dyslipidemia. Unlike Western countries, where coronary artery disease predominantly affects elderly populations, a substantial proportion of Middle Eastern STEMI patients are diagnosed during economically productive years of adulthood. Consequently, premature STEMI imposes substantial long-term socioeconomic and healthcare burdens.[15,21]

The younger age profile also influences disease characteristics because younger patients frequently exhibit different risk factor distributions, fewer chronic comorbidities, and greater potential for long-term survival following successful reperfusion. However, earlier disease onset increases cumulative lifetime risk for recurrent cardiovascular events.[39]

Sex Distribution and Gender Differences

Similar to global observations, STEMI in Egypt and the Middle East predominantly affects men. Smoking prevalence, occupational stress exposure, and earlier development of cardiovascular risk factors among males contribute to this disparity. Nevertheless, women with STEMI often experience worse outcomes due to delayed presentation, atypical symptoms, advanced age at diagnosis, and greater prevalence of comorbidities.[40]

Several studies have demonstrated that women are more likely to present with non-classical symptoms such as dyspnea, fatigue, nausea, vomiting, dizziness, and generalized weakness rather than typical chest pain. These atypical presentations may delay diagnosis and reduce the likelihood of timely reperfusion therapy.[40]

Cultural and socioeconomic factors may further contribute to delayed healthcare seeking among women in certain Middle Eastern societies, emphasizing the need for targeted awareness programs and improved recognition of sex-specific manifestations of acute coronary syndromes.[41]

Symptom Profile and Clinical Manifestations

The classical presentation of STEMI consists of prolonged retrosternal chest pain or pressure lasting more than 20–30 minutes and frequently radiating to the left arm, neck, jaw, shoulder, or back. Associated symptoms commonly include diaphoresis, nausea, vomiting, dyspnea, palpitations, and anxiety.[42]

Despite this classical description, significant variability exists in symptom presentation. Diabetes mellitus, which is highly prevalent throughout the Middle East, contributes substantially to atypical symptomatology. Diabetic autonomic neuropathy may impair pain perception and lead to silent ischemia or less typical clinical manifestations. Consequently, diabetic patients often present later and experience larger infarcts than non-diabetic individuals.[26]

Several regional studies have reported high rates of atypical presentation among elderly patients, women, and individuals with diabetes mellitus. These findings have important clinical implications because atypical symptoms are associated with delayed diagnosis, prolonged ischemic times, and increased mortality.[43]

Delay in Healthcare-Seeking Behavior

One of the most important distinguishing characteristics of STEMI care in Egypt and many Middle Eastern countries is delayed presentation following symptom onset. Total ischemic time remains one of the strongest determinants of infarct size, ventricular function, and survival. Nevertheless, prolonged symptom-to-door intervals continue to represent a major challenge throughout the region.[44]

Numerous factors contribute to delayed healthcare seeking. Lack of public awareness regarding myocardial infarction symptoms, misinterpretation of symptoms as gastrointestinal or musculoskeletal disorders, transportation barriers, socioeconomic constraints, and fear of hospitalization frequently postpone medical evaluation. In some patients, traditional remedies or consultation with non-specialized healthcare providers may further delay definitive treatment.[9]

The consequences of delayed presentation are substantial. Longer ischemic times reduce eligibility for reperfusion therapies, increase infarct size, promote adverse ventricular remodeling, and worsen clinical outcomes. Therefore, public education campaigns emphasizing early recognition of myocardial infarction symptoms remain essential components of cardiovascular prevention strategies.[44]

Emergency Medical Service Utilization

Emergency medical services (EMS) play a critical role in contemporary STEMI systems of care by facilitating rapid diagnosis, prehospital electrocardiography, early triage, and direct transfer to PCI-capable centers. However, EMS utilization remains significantly lower in many Middle Eastern countries than in Europe and North America.[9,17]

The Egyptian STEMI registry demonstrated that many patients continue to arrive at hospitals through self-transport rather than ambulance activation. Similar findings have been reported across several Gulf countries. This pattern delays diagnosis and prevents implementation of organized STEMI pathways that depend on prehospital assessment and early catheterization laboratory activation.[9,13]

In contrast, Western healthcare systems frequently utilize integrated STEMI networks where ambulance personnel perform prehospital ECGs and directly transport patients to PCI-capable facilities. Such systems have significantly reduced treatment delays and improved survival rates.[17]

Improving EMS awareness and utilization therefore represents a major opportunity for enhancing STEMI care throughout the Middle East.[44]

Electrocardiographic Characteristics

Electrocardiography remains the cornerstone of STEMI diagnosis and should be performed immediately upon first medical contact. Typical ECG findings include ST-segment elevation in anatomically contiguous leads, reciprocal ST-segment depression, hyperacute T waves, and eventual development of pathological Q waves.[4]

The distribution of infarct location among Middle Eastern populations generally resembles patterns observed internationally. Anterior wall STEMI, most commonly resulting from left anterior descending artery occlusion, frequently represents the predominant infarct subtype. Inferior STEMI, usually associated with right coronary artery occlusion, constitutes the second most common presentation.[45]

Anterior STEMI is associated with larger infarct size, more extensive myocardial injury, lower left ventricular ejection fraction, and increased risk of heart failure. Consequently, the relatively high frequency of anterior infarction reported in several regional registries may contribute to adverse clinical outcomes.[46]

Laboratory and Biomarker Characteristics

High-sensitivity cardiac troponin remains the preferred biomarker for diagnosing myocardial injury. Elevated troponin concentrations correlate with infarct size and prognosis and have substantially improved diagnostic accuracy for acute myocardial infarction.[42]

Among Middle Eastern STEMI patients, admission hyperglycemia is frequently observed because of the high prevalence of diabetes mellitus and stress-induced metabolic responses. Numerous studies have demonstrated that elevated glucose levels during acute myocardial infarction are associated with increased mortality, greater infarct size, and higher risk of heart failure,

regardless of diabetic status.[47]

Inflammatory biomarkers including high-sensitivity C-reactive protein and leukocyte counts may also provide prognostic information regarding ventricular remodeling and future cardiovascular risk. The growing recognition of inflammation as a central component of atherosclerotic disease has increased interest in these markers as potential therapeutic targets.[35]

Echocardiographic Findings

Echocardiography remains a fundamental component of STEMI evaluation and provides essential information regarding infarct extent, ventricular function, and mechanical complications. The most frequently observed abnormalities include regional wall motion defects, reduced left ventricular ejection fraction, mitral regurgitation, and right ventricular dysfunction.[48]

Several studies have shown that left ventricular ejection fraction remains among the strongest predictors of short-term and long-term mortality after STEMI. Patients with extensive anterior infarction frequently demonstrate greater impairment of ventricular function and consequently face higher risks of heart failure and adverse remodeling.[48]

Echocardiography also facilitates identification of life-threatening complications including ventricular septal rupture, papillary muscle rupture, and free-wall rupture. Although these complications have become less common with contemporary reperfusion therapies, they continue to carry substantial mortality.[49]

Coronary Angiographic Characteristics

Coronary angiography provides definitive identification of culprit lesions and remains the gold standard for guiding reperfusion therapy. Similar to international populations, the left anterior descending artery is the most common culprit vessel among Egyptian and Middle Eastern STEMI patients.[50]

However, because of the high prevalence of diabetes mellitus and metabolic syndrome, multivessel coronary artery disease appears particularly common in many regional cohorts. Diabetic patients frequently exhibit diffuse atherosclerosis, smaller vessel caliber, and more complex coronary anatomy, all of which may influence treatment decisions and long-term outcomes.[26]

The increased prevalence of multivessel disease contributes to higher rates of recurrent ischemia and emphasizes the importance of comprehensive secondary prevention strategies following STEMI.[50]

Diagnostic Challenges Compared with Western Populations

Several diagnostic challenges distinguish STEMI care in Egypt and the Middle East from Western settings. First, delayed healthcare-seeking behavior prolongs total ischemic time. Second, atypical presentations among diabetic patients and women increase the likelihood of missed or delayed diagnosis. Third, limited EMS utilization restricts opportunities for early ECG acquisition and rapid triage. Finally, disparities in healthcare infrastructure may influence access to advanced diagnostic technologies and reperfusion services.[9,17]

These challenges collectively contribute to treatment delays and underscore the importance of strengthening STEMI systems of care throughout the region. Expanding public awareness, improving emergency response systems, increasing healthcare accessibility, and promoting adherence to evidence-based diagnostic pathways are essential for improving outcomes.[44]

In summary, STEMI patients in Egypt and Middle Eastern countries exhibit distinctive clinical and diagnostic characteristics including younger age at presentation, high prevalence of atypical symptoms among diabetic patients, delayed healthcare-seeking behavior, low utilization of emergency medical services, and frequent multivessel coronary disease. These factors differentiate regional populations from Western cohorts and significantly influence treatment strategies and clinical outcomes.

Reperfusion Strategies and Contemporary Management of STEMI in Egypt and Middle Eastern Countries

The management of ST-segment elevation myocardial infarction (STEMI) has undergone remarkable transformation during the past three decades. Contemporary treatment strategies emphasize rapid diagnosis, prompt reperfusion, evidence-based pharmacotherapy, secondary prevention, and integrated systems of care. Despite global advances, substantial regional differences remain in treatment accessibility, reperfusion strategies, healthcare infrastructure, and guideline implementation. Egypt and many Middle Eastern countries have made significant progress in STEMI management; however, important disparities continue to influence clinical outcomes.[51,52]

Principles of STEMI Management

The primary objective of STEMI treatment is restoration of coronary blood flow as rapidly as possible to limit myocardial necrosis, preserve ventricular function, and improve survival. The concept that "time is muscle" remains central to modern STEMI care because treatment delays are directly associated with larger infarct size, increased complications, and higher mortality.[53]

Current international guidelines recommend immediate reperfusion therapy for all eligible patients presenting within the appropriate therapeutic window. Primary percutaneous coronary intervention (PCI) is considered the preferred reperfusion strategy when performed promptly by experienced operators. When timely PCI cannot be achieved, fibrinolytic therapy followed by routine angiography represents an acceptable alternative.[42,54]

Beyond reperfusion, comprehensive STEMI management includes antiplatelet therapy, anticoagulation, lipid-lowering treatment, beta-blockers, renin-angiotensin system inhibition, lifestyle modification, cardiac rehabilitation, and long-term secondary prevention.[54]

Development of STEMI Systems of Care

One of the most important advances in acute myocardial infarction management has been the establishment of organized STEMI networks. These systems integrate emergency medical services, referral hospitals, PCI-capable centers, and catheterization laboratories to minimize treatment delays and optimize patient outcomes.[55]

European and North American healthcare systems have successfully implemented regional STEMI networks that facilitate prehospital diagnosis, direct catheterization laboratory activation, rapid transfer pathways, and continuous quality assessment. These coordinated systems have significantly reduced mortality and improved access to reperfusion therapy.[17,18]

In contrast, many Middle Eastern countries remain in various stages of STEMI network development. Although substantial progress has occurred during the last decade, variations in infrastructure, geography, healthcare resources, and emergency medical service utilization continue to influence performance.[56]

Primary Percutaneous Coronary Intervention

Primary PCI has become the gold-standard reperfusion strategy for STEMI because it provides superior coronary artery patency, lower reinfarction rates, reduced intracranial hemorrhage risk, and improved survival compared with fibrinolytic therapy. Multiple randomized trials have demonstrated the superiority of primary PCI when performed within recommended time intervals.[57]

Current European Society of Cardiology guidelines recommend primary PCI when it can be performed within 120 minutes of STEMI diagnosis. The procedure involves immediate coronary angiography, identification of the culprit lesion, thrombus management, balloon angioplasty, and stent implantation to restore coronary blood flow.[42]

Several Middle Eastern countries have substantially expanded PCI capability during recent years. Major metropolitan centers in Egypt, Saudi Arabia, the United Arab Emirates, Qatar, and Kuwait increasingly provide 24-hour primary PCI services. Consequently, utilization of primary PCI has increased significantly compared with previous decades.[9,14]

Nevertheless, important disparities remain. Urban centers generally possess greater access to catheterization laboratories, whereas rural and remote regions may still rely on thrombolytic therapy because of transportation limitations and resource constraints. These geographic inequalities continue to influence treatment selection and outcomes.[58]

Primary PCI in Egypt

Egypt has witnessed significant growth in interventional cardiology services, with increasing numbers of PCI-capable centers distributed throughout the country. The Egyptian STEMI registry demonstrated increasing adoption of primary PCI, particularly within tertiary referral centers and academic institutions.[9]

Despite these advances, access remains heterogeneous. Geographic disparities, transportation challenges, delayed presentation, and variable emergency medical service utilization may prevent timely access to primary PCI for many patients. Consequently, thrombolytic therapy continues to play an important role within certain healthcare settings.[9]

Expansion of national STEMI networks, improved ambulance utilization, and enhanced coordination between referral centers and PCI-capable hospitals represent important priorities for further improving STEMI care in Egypt.[56]

Fibrinolytic Therapy

Before the widespread availability of PCI, fibrinolytic therapy represented the standard reperfusion treatment for STEMI. Landmark clinical trials demonstrated substantial mortality reduction through early administration of fibrinolytic agents capable of dissolving intracoronary thrombi and restoring blood flow.[59]

Although primary PCI is now preferred, fibrinolysis remains an important therapeutic option when timely PCI cannot be achieved. Current guidelines recommend fibrinolytic therapy when anticipated delays to PCI exceed recommended limits, particularly in regions where catheterization laboratories are not immediately accessible.[42]

Commonly used fibrinolytic agents include:

- Tenecteplase
- Alteplase
- Reteplase
- Streptokinase

Among these agents, fibrin-specific drugs such as tenecteplase generally demonstrate superior efficacy and convenience compared with older agents.[54]

In Egypt and several Middle Eastern countries, fibrinolysis continues to contribute substantially to STEMI management, especially in peripheral hospitals lacking PCI capability. Appropriate patient selection and subsequent transfer for coronary angiography remain critical determinants of success.[58]

Pharmaco-Invasive Strategy

The pharmaco-invasive approach has emerged as an important reperfusion strategy in healthcare systems where universal access to immediate PCI remains challenging. This strategy involves early fibrinolytic therapy followed by routine coronary angiography and PCI within the subsequent 2–24 hours.[60]

Several studies have demonstrated that a pharmaco-invasive strategy may provide outcomes comparable to primary PCI when delays to catheterization are unavoidable. Consequently, this approach has gained increasing acceptance in developing healthcare systems and geographically dispersed regions.[60]

For countries such as Egypt, where substantial variations exist in PCI accessibility, the pharmaco-invasive model offers a practical solution for expanding reperfusion coverage while maximizing available resources.[58]

Antiplatelet Therapy

Platelet activation plays a central role in STEMI pathogenesis, making antiplatelet therapy a cornerstone of management. Aspirin should be administered immediately upon diagnosis and continued indefinitely unless contraindicated.[54]

Dual antiplatelet therapy (DAPT) consisting of aspirin plus a P2Y12 inhibitor is currently recommended following STEMI. Preferred P2Y12 inhibitors include:

- Ticagrelor
- Prasugrel
- Clopidogrel

Contemporary evidence generally favors ticagrelor and prasugrel over clopidogrel because of superior platelet inhibition and improved cardiovascular outcomes.[61]

Implementation of guideline-directed antiplatelet therapy has improved significantly across Middle Eastern countries, although variations in drug availability, affordability, and physician practice patterns continue to influence treatment selection.[62]

Anticoagulation Therapy

Anticoagulant therapy complements antiplatelet treatment by suppressing thrombin generation and limiting thrombus propagation. During STEMI management, anticoagulants are routinely administered in conjunction with reperfusion therapy and

PCI.[54]

Commonly utilized agents include:

- Unfractionated heparin
- Enoxaparin
- Bivalirudin

Selection depends on reperfusion strategy, bleeding risk, procedural considerations, and institutional protocols.[54]

Appropriate anticoagulation reduces recurrent ischemic events while balancing hemorrhagic complications, which remain important determinants of clinical outcomes.[63]

Secondary Prevention Following STEMI

Successful reperfusion alone does not eliminate future cardiovascular risk. Secondary prevention remains essential because survivors of STEMI remain vulnerable to recurrent myocardial infarction, heart failure, stroke, and cardiovascular death. [63]

Evidence-based secondary prevention measures include:

- High-intensity statin therapy
- Beta-blockers
- ACE inhibitors or ARBs
- Mineralocorticoid receptor antagonists when indicated
- Smoking cessation
- Blood pressure control
- Diabetes management
- Weight reduction
- Physical activity promotion

Implementation of these interventions significantly reduces recurrent cardiovascular events and improves long-term survival.[54,63]

Unfortunately, studies from several Middle Eastern countries suggest that long-term adherence to secondary prevention therapies remains suboptimal. Improving medication adherence and follow-up care therefore represents an important opportunity for reducing residual cardiovascular risk.[62]

Cardiac Rehabilitation

Cardiac rehabilitation is a multidisciplinary intervention incorporating exercise training, risk factor modification, psychosocial support, nutritional counseling, and patient education. Numerous studies have demonstrated substantial reductions in mortality and recurrent cardiovascular events among patients participating in structured rehabilitation programs.[61]

Despite proven benefits, cardiac rehabilitation remains underutilized throughout much of the Middle East. Limited program availability, insufficient referral systems, transportation difficulties, and inadequate patient awareness contribute to low participation rates.[61]

Expansion of rehabilitation services should therefore be considered a priority component of comprehensive STEMI care across the region.[60]

Contemporary Challenges in Egypt and the Middle East

Despite significant advances in STEMI management, several challenges continue to influence outcomes throughout the region. These include:

- Delayed patient presentation.

- Low emergency medical service utilization.
- Geographic disparities in PCI access.
- Limited STEMI network coverage.
- Variable adherence to guideline-directed therapy.
- Incomplete participation in cardiac rehabilitation.
- Growing burden of diabetes and obesity.[9,56]

Addressing these challenges requires coordinated national strategies involving healthcare systems, policymakers, professional societies, and public health organizations.[62]

Comparison with Western Countries

Compared with Europe and North America, contemporary STEMI management in Egypt and many Middle Eastern countries has improved substantially but remains characterized by greater heterogeneity. Western healthcare systems generally achieve higher rates of primary PCI utilization, shorter treatment delays, broader emergency medical service engagement, and more mature STEMI networks.[17,18]

However, several Gulf countries have recently achieved significant improvements and increasingly approach international standards of STEMI care. Continued investment in healthcare infrastructure, workforce development, and regional STEMI programs may further narrow existing gaps.[14]

Overall, the management of STEMI in Egypt and the Middle East has undergone substantial evolution during recent decades. Expansion of primary PCI services, increasing guideline adherence, and growing recognition of organized STEMI systems have improved outcomes. Nevertheless, continued efforts are required to overcome persistent barriers and ensure equitable access to timely, evidence-based cardiovascular care throughout the region.

Clinical Outcomes and Prognosis of STEMI in Egypt and Middle Eastern Populations

Clinical outcomes following ST-segment elevation myocardial infarction (STEMI) have improved substantially over recent decades because of advances in reperfusion therapy, pharmacological treatment, and secondary prevention. Nevertheless, significant regional differences persist in mortality, complications, and long-term prognosis. These variations are influenced by demographic characteristics, cardiovascular risk profiles, healthcare infrastructure, treatment delays, and access to evidence-based therapies.[60]

In-Hospital Mortality

In-hospital mortality remains one of the most important indicators of STEMI care quality. Contemporary registries from Europe and North America report substantial reductions in mortality owing to widespread implementation of primary percutaneous coronary intervention (PCI) and organized STEMI networks. In contrast, outcomes across Middle Eastern countries remain more heterogeneous because of differences in healthcare accessibility and reperfusion strategies.[59]

Data from the Egyptian STEMI registry demonstrated that mortality was strongly influenced by reperfusion status. Patients receiving timely primary PCI experienced the most favorable outcomes, whereas mortality was highest among individuals who did not receive reperfusion therapy. These findings emphasize the critical importance of rapid diagnosis and timely restoration of coronary blood flow.[9]

Heart Failure and Left Ventricular Dysfunction

Heart failure remains one of the most common complications following STEMI and is a major determinant of long-term prognosis. The risk of heart failure is strongly associated with infarct size, delayed reperfusion, anterior wall infarction, and reduced left ventricular ejection fraction.[61]

Because delayed presentation remains relatively common in several Middle Eastern countries, a substantial proportion of patients continue to experience significant myocardial injury before reperfusion can be achieved. Consequently, heart failure contributes considerably to morbidity, hospital readmissions, and healthcare expenditures following STEMI.[44]

Cardiogenic Shock

Cardiogenic shock represents the most severe complication of acute myocardial infarction and continues to carry a high mortality rate despite advances in contemporary treatment. Patients presenting with cardiogenic shock require urgent revascularization, intensive hemodynamic support, and multidisciplinary management.[60]

Although the incidence of cardiogenic shock has declined modestly with earlier reperfusion, mortality remains substantial worldwide. Outcomes are particularly dependent on rapid recognition and access to advanced cardiovascular care facilities.[62]

Reinfarction and Recurrent Ischemic Events

Recurrent myocardial infarction remains an important determinant of long-term prognosis. Persistent smoking, poorly controlled diabetes mellitus, inadequate lipid management, and poor medication adherence contribute significantly to recurrent ischemic events in Middle Eastern populations. [63]

Implementation of guideline-directed secondary prevention strategies, including high-intensity statin therapy, dual antiplatelet therapy, smoking cessation, and aggressive risk factor modification, has been associated with substantial reductions in reinfarction rates and cardiovascular mortality[63]

Long-Term Outcomes

Long-term prognosis following STEMI is influenced by age, diabetes mellitus, left ventricular function, extent of coronary artery disease, and adherence to secondary prevention therapies. Although survival has improved significantly, patients from Egypt and the Middle East remain exposed to a high burden of recurrent cardiovascular risk because of the persistent prevalence of smoking, obesity, diabetes mellitus, and metabolic syndrome[63]

Several regional studies suggest that improving secondary prevention and cardiac rehabilitation participation may offer one of the greatest opportunities for enhancing long-term outcomes after STEMI. [60]

Regional Perspective

Compared with Western populations, STEMI patients in Egypt and the Middle East generally present at younger ages but often exhibit a heavier burden of cardiometabolic risk factors. While advances in primary PCI and contemporary pharmacotherapy have improved survival, delays in presentation and variability in healthcare access continue to influence outcomes. Ongoing expansion of STEMI networks, improved emergency medical service utilization, and stronger preventive cardiology programs are expected to further reduce mortality and complications throughout the region.[9,56]

Conclusion

ST-segment elevation myocardial infarction in Egypt and Middle Eastern populations exhibits distinctive epidemiological, clinical, and therapeutic characteristics compared with Western populations. Patients typically present at younger ages and carry a disproportionately high burden of smoking, diabetes mellitus, obesity, metabolic syndrome, and other cardiometabolic risk factors that accelerate atherosclerotic disease progression. Although substantial advances have been achieved in reperfusion therapy, primary PCI availability, and guideline-directed management, challenges including delayed presentation, underutilization of emergency medical services, disparities in healthcare access, and suboptimal implementation of secondary prevention continue to influence outcomes. Addressing these challenges through aggressive risk factor control, expansion of STEMI networks, enhancement of public awareness, improved emergency cardiovascular care systems, and broader access to evidence-based therapies will be essential for reducing STEMI-related morbidity and mortality and improving cardiovascular health across the region.

How to cite this article: Moataz A. Elkot, Muhammad Wafaie Aboleineen, Ahmed Shawky Shereef, Basel Hatem Saadel Din Muhammad (2024). Distinctive Features of ST-Segment Elevation Myocardial Infarction: Epidemiology, Risk Profiles, Management, and Outcomes. Vol. 14, No. 3, 2024,1144--1160.

Source of support: None.

Conflict of interest: Nil.

Accepted: 26.03.2024 **Received** 03.03.2024

REFERENCES

1. World Health Organization. Cardiovascular diseases (CVDs). World Health Organization. Accessed June 2026.
2. Joseph P, Leong D, McKee M, Anand SS, Schwalm JD, Teo K, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res. 2017;121(6):677-694.
3. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). Eur Heart J. 2019;40(3):237-269.
4. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826.
5. Elendu C, Amaechi DC, Ajao O, et al. Global epidemiology and burden of ST-segment elevation myocardial infarction. Cureus. 2023;15:e45023.
6. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J. 2016;37(42):3232-3245.
7. Ralapanawa U, Kumarasiri PVR, Jayawickreme KP, et al. Epidemiology and risk factors of acute coronary syndrome. Int J Cardiol Heart Vasc. 2019;22:1-8.
8. Bellary S, O'Hare JP, Raymond NT, et al. Premature cardiovascular events and mortality in South Asians with type 2 diabetes. Curr Med Res Opin. 2010;26(8):1873-1879.
9. Shaheen SM, ElGuindy AM, Elhadidy A, et al. Characteristics, management, and outcomes of STEMI patients in Egypt compared with ESC member countries. Eur Heart J Acute Cardiovasc Care. 2020.
10. Mokdad AH, Jaber S, Aziz MI, et al. The state of health in the Arab world. Lancet. 2014;383(9914):309-320.
11. Zubaid M, Rashed WA, Al-Khaja N, et al. Clinical presentation and outcomes of acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE). Heart Views. 2009;10:93-98.
12. Alhabib KF, Sulaiman K, Al-Motarreb A, et al. Baseline characteristics, management practices, and outcomes of acute coronary syndrome in the Gulf region. Eur Heart J Acute Cardiovasc Care. 2015;4(5):477-488.
13. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (INTERHEART study). Lancet. 2004;364(9438):937-952.
14. Maziak W, Ward KD, Afifi Soweid RA, Eissenberg T. Tobacco smoking using a waterpipe: a re-emerging health threat. Tob Control. 2004;13(4):327-333.
15. Onor IO, Stirling DL, Williams SR, et al. Clinical effects of cigarette smoking: epidemiologic impact and review. Int J Environ Res Public Health. 2017;14(10):1147.
16. Hbejan K. Smoking effect on ischemic heart disease in young patients. Heart Views. 2011;12(1):1-6.
17. Widimský P, Wijns W, Fajadet J, de Belder M, Knot J, Aaberge L, et al. Reperfusion therapy and STEMI systems of care. Eur Heart J. 2014;35(15):949-957.
18. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Circulation. 2013;127:e362-e425.
19. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics update. Circulation. 2021;143:e254-e743.
20. McKeigue PM, Marmot MG. Mortality from coronary heart disease in South Asians. BMJ. 1989;298:1144-1145.
21. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2021.
22. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in diabetic and non-diabetic populations. Lancet. 2006;368(9529):29-36.
23. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009;2(5-6):231-237.
24. Laaksonen DE, Lakka HM, Niskanen LK, et al. Metabolic syndrome and cardiovascular disease risk. Am J Cardiol. 2002;89(6):509-512.
25. Lawes CMM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease. Lancet. 2008;371(9623):1513-1518.
26. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-237.
27. Abera A, Worede A, Hirigo AT, et al. Dyslipidemia and associated cardiovascular risk factors. Eur J Med Res. 2024;29:1-11.
28. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188.
29. Vernon ST, Coffey S, D'Souza M, et al. Genetic determinants of coronary artery disease. Heart Lung Circ. 2019;28(1):1-15.
30. Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): a genetically determined cardiovascular risk factor. J Am Coll Cardiol. 2022;79(22):2230-2248.
31. Ridker PM. Inflammation and cardiovascular disease. Circ Res. 2014;114(4):594-595.

32. Askin L. Coronary artery disease, depression, anxiety and psychosocial determinants. North Clin Istanb. 2020;7(4):363-368.
33. Shah N, Kelly AM, Cox N, Wong C, Soon K. Myocardial infarction in young adults. Heart Lung Circ. 2016;25(10):955-960.
34. Chandrasekhar J, Gill A, Mehran R. Acute myocardial infarction in women. Curr Atheroscler Rep. 2018;20(8):1-10.
35. Mehta LS, Beckie TM, DeVon HA, et al. Acute myocardial infarction in women. Circulation. 2016;133(9):916-947.
36. Canto JG, Shlipak MG, Rogers WJ, et al. Prevalence and outcomes of myocardial infarction without chest pain. JAMA. 2000;283(24):3223-3229.
37. Birnbaum Y, Drew BJ. The electrocardiogram in ST-elevation myocardial infarction. Circulation. 2003;107(25):324-326.
38. Grech ED, Ramsdale DR. Acute myocardial infarction: diagnosis and management. BMJ. 2003;326(7404):1379-1381.
39. Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in acute myocardial infarction. Circulation. 2005;111(23):3078-3086.
40. Greaves K. Role of echocardiography in acute myocardial infarction. Heart. 2002;88(4):419-425.
41. Figueras J, Alcalde O, Barrabés JA, et al. Mechanical complications after STEMI. Eur Heart J Acute Cardiovasc Care. 2020;9(Suppl):S86-S95.
42. Niccoli G, Scalone G, Lerman A, Crea F. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J. 2016;37(13):1024-1033.
43. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for STEMI management. Eur Heart J. 2018;39(2):119-177.
44. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty. Circulation. 2004;109(10):1223-1225.
45. Terkelsen CJ, Sørensen JT, Maeng M, et al. System delay and mortality in STEMI. JAMA. 2010;304(7):763-771.
46. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy. Lancet. 2003;361(9351):13-20.
47. Armstrong PW, Gershlick AH, Goldstein P, et al. STREAM trial. N Engl J Med. 2013;368(15):1379-1387.
48. Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction. Lancet. 1994;343(8893):311-322.
49. Borgia F, Goodman SG, Halvorsen S, et al. Early routine PCI after fibrinolysis in STEMI. Eur Heart J. 2010;31(17):2156-2169.
50. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in ACS. N Engl J Med. 2009;361(11):1045-1057.
51. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in ACS. N Engl J Med. 2007;357(20):2001-2015.
52. Steg PG, van't Hof A, Hamm CW, et al. Bivalirudin versus heparin in STEMI. Lancet. 2013;382(9892):524-533.
53. Smith SC Jr, Benjamin EJ, Bonow RO, et al. Secondary prevention and risk reduction therapy. Circulation. 2011;124(22):2458-2473.
54. Chow CK, Jolly S, Rao-Melacini P, et al. Medication adherence after acute coronary syndrome. Eur Heart J. 2013;34(38):294-300.
55. Anderson L, Oldridge N, Thompson DR, et al. Exercise-based cardiac rehabilitation. J Am Coll Cardiol. 2016;67(1):1-12.
56. Turk-Adawi K, Supervia M, Lopez-Jimenez F, et al. Cardiac rehabilitation availability and density around the globe. EClinicalMedicine. 2019;13:31-45.
57. Yusuf S, Joseph P, Rangarajan S, et al. Cardiovascular prevention challenges in low- and middle-income countries. Lancet. 2021;398(10304):123-142.
58. Puymirat E, Simon T, Cayla G, et al. Acute myocardial infarction: changes in patient characteristics, management and outcomes. Eur Heart J. 2017;38(13):983-995.
59. Fox KAA, Carruthers KF, Dunbar DR, et al. Prognosis of acute coronary syndrome. Eur Heart J. 2010;31(22):2755-2764.
60. Jernberg T, Johanson P, Held C, et al. Association between reperfusion strategy and mortality in STEMI. Eur Heart J. 2011;32(12):1486-1494.
61. McMurray JJV, Pfeffer MA. Heart failure after myocardial infarction. Circulation. 2005;112(24):374-381.
62. Thiele H, Ohman EM, Desch S, Eitel I, de Waha S. Management of cardiogenic shock complicating myocardial infarction. Lancet. 2015;385(9976):1561-1572.
63. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients. Eur Heart J. 2015;36(19):1163-1170.